AI Article Synopsis
- The need for a universal influenza vaccine is underscored by recent pandemics and cases of various H5 and H7 strains in Asia.
- Researchers demonstrated that a recombinant monoglycosylated hemagglutinin (HAmg) vaccine provides effective cross-strain protection against various H1N1 viruses from 1933 to 2009 in animal models.
- The HAmg vaccine enhances immune responses by exposing conserved protein sequences, activating a diverse B-cell response, and inducing robust T cell and antibody production, potentially reducing the need for yearly vaccine reformulations.
Article Abstract
The 2009 H1N1 pandemic and recent human cases of H5N1, H7N9, and H6N1 in Asia highlight the need for a universal influenza vaccine that can provide cross-strain or even cross-subtype protection. Here, we show that recombinant monoglycosylated hemagglutinin (HAmg) with an intact protein structure from either seasonal or pandemic H1N1 can be used as a vaccine for cross-strain protection against various H1N1 viruses in circulation from 1933 to 2009 in mice and ferrets. In the HAmg vaccine, highly conserved sequences that were originally covered by glycans in the fully glycosylated HA (HAfg) are exposed and thus, are better engulfed by dendritic cells (DCs), stimulated better DC maturation, and induced more CD8+ memory T cells and IgG-secreting plasma cells. Single B-cell RT-PCR followed by sequence analysis revealed that the HAmg vaccine activated more diverse B-cell repertoires than the HAfg vaccine and produced antibodies with cross-strain binding ability. In summary, the HAmg vaccine elicits cross-strain immune responses that may mitigate the current need for yearly reformulation of strain-specific inactivated vaccines. This strategy may also map a new direction for universal vaccine design.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932897 | PMC |
| http://dx.doi.org/10.1073/pnas.1323954111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets.
Vaccines (Basel)
August 2022
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361102, China.
Recent efforts have been directed toward the development of universal influenza vaccines inducing broadly neutralizing antibodies to conserved antigenic supersites of Hemagglutinin (HA). Although several studies raise the importance of glycosylation in HA antigen design, whether this theory can be widely confirmed remains unclear; which influenza HA with an altered glycosylation profile could impact the amplitude and focus of the host immune response. Here, we evaluated the characteristics and efficacy of deglycosylated modified HA proteins, including monoglycosylated HA (HA), unglycosylated HA (HA), and fully glycosylated HA (HA), without treatment with H3N2 Wisconsin/67/2005.
View Article and Find Full Text PDFEgg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections.
Proc Natl Acad Sci U S A
March 2019
Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan
Each year influenza virus infections cause hundreds of thousands of deaths worldwide and a significant level of morbidity with major economic burden. At the present time, vaccination with inactivated virus vaccine produced from embryonated chicken eggs is the most prevalent method to prevent the infections. However, current influenza vaccines are only effective against closely matched circulating strains and must be updated and administered yearly.
View Article and Find Full Text PDFVaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections.
Proc Natl Acad Sci U S A
February 2014
Genomics Research Center, Academia Sinica, Taipei 115, Taiwan.
The 2009 H1N1 pandemic and recent human cases of H5N1, H7N9, and H6N1 in Asia highlight the need for a universal influenza vaccine that can provide cross-strain or even cross-subtype protection. Here, we show that recombinant monoglycosylated hemagglutinin (HAmg) with an intact protein structure from either seasonal or pandemic H1N1 can be used as a vaccine for cross-strain protection against various H1N1 viruses in circulation from 1933 to 2009 in mice and ferrets. In the HAmg vaccine, highly conserved sequences that were originally covered by glycans in the fully glycosylated HA (HAfg) are exposed and thus, are better engulfed by dendritic cells (DCs), stimulated better DC maturation, and induced more CD8+ memory T cells and IgG-secreting plasma cells.
View Article and Find Full Text PDF[Properties of an acellular preparation of Bordetella pertussis and its analysis after centrifugation in saccharose gradient].
Med Dosw Mikrobiol
June 1994
Centralne Laboratorium Surowic i Szczepionek, Warszawie.
Acellular preparations were studied which were obtained by a method of acidic extraction from culture of strain Tohama of Bordetella pertussis. Obtained preparations EM I and EM II were exhibiting property of leukocytosis stimulation and were respectively of following values: 43.5 and 19 u LPF/mg of protein.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!